S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

OTCMKTS:BRRGF - BerGenBio ASA Stock Price, Forecast & News

$1.60
0.00 (0.00 %)
(As of 02/11/2020)
Today's Range
$1.60
Now: $1.60
$1.60
50-Day Range
$1.60
MA: $1.60
$1.60
52-Week Range N/A
Volume1,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing BGB149, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BRRGF
CUSIPN/A
CIKN/A
Phone47 53 50 15 64

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BRRGF News and Ratings via Email

Sign-up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter.


BerGenBio ASA (OTCMKTS:BRRGF) Frequently Asked Questions

What is BerGenBio ASA's stock symbol?

BerGenBio ASA trades on the OTCMKTS under the ticker symbol "BRRGF."

What is the consensus analysts' recommendation for BerGenBio ASA?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BerGenBio ASA.

Has BerGenBio ASA been receiving favorable news coverage?

Headlines about BRRGF stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BerGenBio ASA earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for BerGenBio ASA.

Who are some of BerGenBio ASA's key competitors?

Who are BerGenBio ASA's key executives?

BerGenBio ASA's management team includes the folowing people:
  • Mr. Richard Godfrey, Chief Exec. Officer
  • Prof. James B. Lorens, Co-Founder & Chief Scientific Officer
  • Mr. Rune Skeie, Chief Financial Officer (Age 45)
  • Dr. James Barnes Ph.D., Director of Operations
  • Ms. Debbie Molyneux, Interim HR Director

How do I buy shares of BerGenBio ASA?

Shares of BRRGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BerGenBio ASA's stock price today?

One share of BRRGF stock can currently be purchased for approximately $1.60.

What is BerGenBio ASA's official website?

The official website for BerGenBio ASA is http://www.bergenbio.com/.

How can I contact BerGenBio ASA?

The company can be reached via phone at 47 53 50 15 64.


MarketBeat Community Rating for BerGenBio ASA (OTCMKTS BRRGF)

Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  6
MarketBeat's community ratings are surveys of what our community members think about BerGenBio ASA and other stocks. Vote "Outperform" if you believe BRRGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRRGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel